Abstract: The invention refers to a fully human miniantibody (scFv), called Erbicin, specific for the receptor ErbB2, with a pharmacological, in particular antitumour, activity. It has been obtained from a larger fagmidic library (Griffin 1.) (19) of human synthetic scFv by panning (affinity selection on antigen) carried out on live cells that express various levels of ErbB2. The invention relates also to the DNA and amino acid sequences of said antibody, to the procedure for isolating it, to its use in therapy.

Abstract: The invention refers to a fully human miniantibody (scFv), called Erbicin, specific for the receptor ErbB2, with a pharmacological, in particular antitumour, activity. It has been obtained from a larger fagmidic library (Griffin 1.) (19) of human synthetic scFv by panning (affinity selection on antigen) carried out on live cells that express various levels of ErbB2. The invention relates also to the DNA and amino acid sequences of said antibody, to the procedure for isolating it, to its use in therapy.

Abstract: The invention refers to a fully human miniantibody (scFv), called Erbicin, specific for the receptor ErbB2, with a pharmacological, in particular antitumour, activity. It has been obtained from a larger fagmidic library (Griffin 1.) (19) of human synthetic scFv by panning (affinity selection on antigen) carried out on live cells that express various levels of ErbB2. The invention relates also to the DNA and aniino acid sequences of said antibody, to the procedure for isolating it, to its use in therapy.

Abstract: Compounds are provided for use in the diagnosis and/or therapy of tumors and/or as immunosuppressive agent. The compounds are antibodies which bind to IL-4 receptors and IL-4 receptor-binding fragments thereof. A preferred compound is monoclonal antibody MR-6 produced by the hybridoma deposited at the European Collection of Animal Cell Cultures with the accession number 88033002. The invention also extends to the use of the compounds for in vitro removal of graft-versus-host reactive T-lymphocytes prior to bone marrow transplantation and to a novel protein of molecular weight 200,000 daltons functioning as a receptor for IL-4.

Abstract: The invention provides compounds for use in the diagnosis and/or therapy of tumors and/or as an immunosuppressant agent selected from the group consisting of antibodies which bind to IL-4 receptors and IL-4 receptor-binding fragments thereof. A preferred such compound is monoclonal antibody MR6 produced by the hybridoma deposited at the European Collection of Animal Cell Cultures with the accession number 88033002. The invention also extends to the use of the compounds for in vitro removal of graft-versus-host reactive T-lymphocytes prior to bone marrow transplantation and to a novel protein of molecular weight 200,000 daltons functioning as a receptor for IL-4.